Full Schedule

6:00 AM - 6:45 AM PDT

Wellness Class- Strength & Stretch

Location: Exhibit Hall Foyer

6:00 AM - 6:30 PM PDT

Meditation & Quiet Room

Location: 326

6:00 AM - 6:30 PM PDT

Registration Open

Location: Summit Lobby

6:30 AM - 8:30 AM PDT

EnVision Faculty & Trainee Breakfast

Location: 304-Calawah (Hyatt Regency)

7:00 AM - 9:30 AM PDT

DIGEST Faculty & Trainee Breakfast

Location: 303-Bogachiel (Hyatt Regency)

7:45 AM - 9:00 AM PDT

Registry Classroom- Registry Data Update

Location: 602-Nooksack (Hyatt Regency)

7:45 AM - 9:45 AM PDT

AF1- Screening for CF Among Our Patients with Bronchiectasis: An Unmet Need

Location: Ballroom 1 (Level 5)

Speaker: – Columbia University Medical Center

7:45 AM - 9:45 AM PDT

AF2- Beyond Infection & Inflammation: Malignancy in the Differential for Chest CT Abnormalities in CF

Location: Ballroom 1 (Level 5)

Speaker: – University of Miami/Jackson Memorial Hospital

7:45 AM - 9:45 AM PDT

AF3- Gastrointestinal Malignancy: Risk Stratification & Screening in People with CF

Location: Ballroom 1 (Level 5)

Speaker: – University of Minnesota

7:45 AM - 9:45 AM PDT

AF4- Recurrent Abdominal Pain in a CF Patient with a History of Non-tuberculous Mycobacterial Pulmonary Disease

Location: Ballroom 1 (Level 5)

Speaker: – Brigham and Women's Hospital

7:45 AM - 9:45 AM PDT

AF5- Recurrent Pancreatitis in a CFTR Heterozygote: Clinical Response to CFTR Modulator Therapy & Discordant Biomarker Response

Location: Ballroom 1 (Level 5)

Speaker:

7:45 AM - 9:45 AM PDT

AF6- Hypereosinophilic syndrome in a patient with cystic fibrosis: A rare case of cardiac involvement and response to mepolizumab

Location: Ballroom 1 (Level 5)

Speaker: – Rabin Medical Center

7:45 AM - 9:45 AM PDT

AF7- Administration of Elexacaftor/Tezacaftor/Ivacaftor in a CFTR Carrier Mother for Treatment of Meconium Ileus in a F508del Fetus with Extension of Therapy into the Postpartum Period

Location: Ballroom 1 (Level 5)

Speaker: – SSM St. Louis University Hospital

7:45 AM - 9:45 AM PDT

AF--Adult Fellows

Location: Ballroom 1 (Level 5)

Chair: – Johns Hopkins University

Chair: – University of Pittsburgh

Facilitator: – MedStar/Georgetown - Washington Hospital Center

CLIN

7:45 AM - 9:45 AM PDT

PF--Pediatric Fellows

Location: Flex A (Level 2)

Chair:

Chair: – The Hospital for Sick Children

Facilitator: – Boston Children's Hospital

CLIN

7:45 AM - 9:45 AM PDT

PF1- Constipation or Complication: When to think outside the box

Location: Flex A (Level 2)

Speaker: – Cincinnati Children's Hospital

7:45 AM - 9:45 AM PDT

PF2- What’s all the rash about? A case of suspected CF dermatitis arthritis syndrome (CF-DAS) in a pediatric patient

Location: Flex A (Level 2)

Speaker: – Ann & Robert H. Lurie Children's Hospital of Chicago, McGaw Medical Center of Northwestern University

7:45 AM - 9:45 AM PDT

PF3- The comeback kid: Pulmonary and pancreatic restoration in a school-aged child with CF on long-term highly effective modulator therapy

Location: Flex A (Level 2)

Speaker: – Emory University / Children’s Healthcare of Atlanta

7:45 AM - 9:45 AM PDT

PF4- ETI and the styes

Location: Flex A (Level 2)

Speaker: – Atrium Health Wake Forest Baptist

7:45 AM - 9:45 AM PDT

PF5- A pediatric patient with cystic fibrosis with elevated sweat chloride levels despite elexacaftor- tezacaftor-ivacaftor therapy

Location: Flex A (Level 2)

Speaker: – Nationwide Children's Hospital

7:45 AM - 9:45 AM PDT

PF6- ‘Fungal disease; not just an innocent bystander in CF’

Location: Flex A (Level 2)

Speaker: – Royal Brompton Hospital

7:45 AM - 9:45 AM PDT

PF7- A case of recurrent massive hemoptysis and bronchiectasis in a toddler with CF treated with bronchial artery embolization and lobectomy

Location: Flex A (Level 2)

Speaker: – UPMC Children's Hospital of Pittsburgh

7:45 AM - 9:45 AM PDT

W16--Host Response to CF Airway Infections

Location: Signature Room (Level 5)

Chair: – McGIll University

Chair: – Rutgers New Jersey Medical School

IMI

7:45 AM - 9:45 AM PDT

W16.1- Hidden in plain sight: Rediscovering Mast Cells in CF

Location: Signature Room (Level 5)

Speaker: – Emory University

7:45 AM - 9:45 AM PDT

W16.2- CFTR modulator impact on naive T cell programming

Location: Signature Room (Level 5)

Speaker: – National Jewish Health

7:45 AM - 9:45 AM PDT

W16.3- Evolution and pathoadaptation of Pseudomonas aeruginosa through the gut-lung axis in CF

Location: Signature Room (Level 5)

Speaker: – Dartmouth College

7:45 AM - 9:45 AM PDT

W16.4- Displacement of methicillin-resistant Staphylococcus aureus following ETI treatment for CF

Location: Signature Room (Level 5)

Speaker: – University of Iowa

7:45 AM - 9:45 AM PDT

W16.5- Tracking Pseudomonas aeruginosa adaptation under CFTR modulator therapy: a longitudinal multi-omics study

Location: Signature Room (Level 5)

Speaker: – Infections and Cystic Fibrosis Unit, San Raffaele Scientific Institute

7:45 AM - 9:45 AM PDT

W17--Extrapulmonary Manifestations & Mechanisms

Location: 427-429

Chair: – Case Western Reserve University

Chair: – University of Virginia

EPPPTAC/CFTR

7:45 AM - 9:45 AM PDT

W17.1- Neurological outcomes of in-utero treatment with ETI

Location: 427-429

Speaker: – Case Western Reserve University

7:45 AM - 9:45 AM PDT

W17.2- Disruption of hippocampal function by ETI therapy

Location: 427-429

Speaker: – University of Saskatchewan

7:45 AM - 9:45 AM PDT

W17.3- Antigen-experienced CD4+ T cell clonal expansion characterizes CF-related diabetes

Location: 427-429

Speaker: – University of Alabama at Birmingham

7:45 AM - 9:45 AM PDT

W17.4- Absent CFTR function is associated with progressive kidney injury and abnormal mineral metabolism in an in vivo mouse model

Location: 427-429

Speaker: – University of Virginia

7:45 AM - 9:45 AM PDT

W17.5- Leaky gut, dysbiosis, and inflammation support inter-organ communication in CF

Location: 427-429

Speaker: – San Raffaele Scientific Institute

7:45 AM - 9:45 AM PDT

DG13--Double Take: Challenging CF Cases Worth Another Look

Location: 320-322

Chair: – Intermountain Health

Chair: – Nebraska Regional Pediatric CF Center

Speaker: – University of Utah Health

Speaker: – Yale New Haven Health

Speaker: – Northwell Health

Speaker: – Primary Children's Hospital

PHARM

7:45 AM - 9:45 AM PDT

DG14--Delivering CF Care in Low & Middle Income Countries

Session includes an in person invitee/speaker with CF

Location: 343-344

Chair: – University of Michigan Health

Chair: – Children's of Alabama

Speaker: – University of Michigan Health

Speaker: – Stanford Children's Hospital

Speaker: – Hospital Dr. H. Notti

Speaker: – UAB Department of Pediatrics

Community Speaker: – Boston Children's Hospital

NRS

7:45 AM - 9:45 AM PDT

DG15--A New Spin on Classic CF Nutrition Care

Location: 331-332

Chair: – Johns Hopkins Hospital

Chair: – Corewell Health

Speaker: – Children's Hospital of Philadelphia

Speaker: – Primary Children's Hospital

Speaker: – Medical University of South Carolina

Community Speaker: – Corewell Health

NTR

7:45 AM - 9:45 AM PDT

DG16--APP Grand Rounds- Enhancing Lives Through Expertise: The Integral Role of Advanced Practice Providers in CF Care

Location: 345-346

Chair: – Baylor College of Medicine

Chair: – Akron Children's

Speaker: – The Royal Children's Hospital, Melbourne, Australia

Speaker: – Baylor College of Medicine

Speaker: – Advocate Children's Hospital

Speaker: – Baylor College of Medicine

Speaker: – University of Kentucky Department of Pediatrics Division of Pulmonary Medicine

Speaker: – Baylor College of Medicine

NRS

7:45 AM - 9:45 AM PDT

DG17--Seeing More Than CF 3.0

Location: 340-342

Chair: – Children's of Alabama

Chair: – Nemours Children's Hospital~Delaware

Speaker: – Massachusetts General Hospital/Harvard Medical School

Speaker: – Washington University School of Medicine

Speaker: – Children's Hospital of Philadelphia

Speaker: – The Hospital for Sick Children

PT&RT

7:45 AM - 9:45 AM PDT

DG18--Psychology/Psychiatry Networking & Knowledge

Location: 335-336

Chair: – UNC Medical Center

Chair: – Nemours Children's Health

Speaker: – Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

Speaker: – Cincinnati Children's Hospital Medical Center, Divisions of Behavioral Medicine and Clinical Psychology & Pulmonary Medicine

Speaker: – Medical University of South Carolina

Speaker:

SW/PSYCH

7:45 AM - 9:45 AM PDT

DG19--Everything You Ever Wanted to Know (& more!) About CFTR Variant Interpretation

Location: 447-448

Chair: – Mayo Clinic

Chair: – Ann & Robert H. Lurie Children's Hospital of Chicago

Speaker: – Ann & Robert H. Lurie Children's Hospital of Chicago

Speaker: – Mayo Clinic

Speaker: – Johns Hopkins University

Speaker: – Newborn Screening Program, Wadsworth Center, New York State Department of Health

CLIN

7:45 AM - 9:45 AM PDT

DG20--It's Important to be Dense: Nutrition & Exercise to Improve Bone Density & Working with Other Endocrine Issues

Location: 347-348

Chair: – Primary Children's Hospital

Chair: – Adult Cystic Fibrosis Center of Central Texas

Speaker: – Dell Children's Medical Center

Speaker: – Medical University of South Carolina

Speaker: – UTSW

PT&RT

7:45 AM - 9:45 AM PDT

DG21--Social Work Networking & Knowledge

Location: 333-334

Chair: – Children's Hospital of Michigan

Chair: – Nemours Children's Health - Orlando

Speaker: – BreatheStrong CF

Speaker: – Cystic Fibrosis Foundation

Speaker: – The Bonnell Foundation: Living with cystic fibrosis

SW/PSYCH

7:45 AM - 9:45 AM PDT

DG22--Tech in Research

Location: 327-329

Chair: – National Jewish Health

Chair: – Boston Children's Hospital

Chair: – University of Pittsburgh

Speaker: – UNC-Chapel Hill

Speaker: – University of North Carolina at Chapel Hill

Speaker: – West Virginia University Department of Pediatrics

Speaker: – Northwestern University

Speaker: – University of Pennsylvania Perelman School of Medicine

CLIN

9:00 AM - 9:50 AM PDT

RFPT06--New Advances in Stem Cell Biology

Location: Theater C Exhibit Hall in the Exhibit Hall

Chair: – University of Alabama at Birmingham

Chair: – Boston University/Boston Medical Center

PTAC/CFTRAPPTT

9:00 AM - 9:50 AM PDT

RFPT06.1- Basal progenitor cells in the ferret trachea and bronchi retain cell-intrinsic programming for goblet cell specification

Location: Theater C Exhibit Hall in the Exhibit Hall

Speaker: – University Of Iowa

9:00 AM - 9:50 AM PDT

RFPT06.2- Unlocking airway stem cell potential by manipulating Ncf1/Igfbp2 signaling

Location: Theater C Exhibit Hall in the Exhibit Hall

Speaker: – University of Iowa

9:00 AM - 9:50 AM PDT

RFPT06.3- Restoration of in vivo CFTR function by tracheal basal cell engraftment

Location: Theater C Exhibit Hall in the Exhibit Hall

Speaker: – Boston University School of Medicine

9:00 AM - 9:50 AM PDT

RFPT06.4- Targeted pre-conditioning and cell transplantation in the murine lower respiratory tract

Location: Theater C Exhibit Hall in the Exhibit Hall

Speaker: – University of Pittsburgh/UPMC

9:00 AM - 9:50 AM PDT

RFPT06.5- Simultaneous inhibition of DNA-PKcs and 53BP1 enables the enrichment-free replacement of the CFTR cDNA in airway basal stem cells

Location: Theater C Exhibit Hall in the Exhibit Hall

Speaker: – Center for Gene Therapy at Nationwide Children's Hospital

9:00 AM - 9:50 AM PDT

RFPT06.6- Targeted gene insertion for functional CFTR restoration in CF airway epithelium

Location: Theater C Exhibit Hall in the Exhibit Hall

Speaker: – University of Alabama at Birmingham

9:00 AM - 9:50 AM PDT

RFPT06.7- Investigating the potential effects of CFTR mutations on pancreatic lineage commitment to elucidate the developmental origins of CFRD

Location: Theater C Exhibit Hall in the Exhibit Hall

Speaker: – University of Toronto

9:00 AM - 9:50 AM PDT

RFPT06.8- A personalized approach to CFTR modulator therapy on CFTR-driven pancreatic dysfunction

Location: Theater C Exhibit Hall in the Exhibit Hall

Speaker: – Cedars-Sinai Medical Center

9:00 AM - 9:50 AM PDT

RFPT07--Topics Related to Health Equity, Cost, Access, & International Issues

Location: Theater B in the Exhibit Hall

Chair: – UCLA

Chair: – University of Washington

HEACSW/PSYCH

9:00 AM - 9:50 AM PDT

RFPT07.1- Housing insecurity in people with CF: Data from the COST-CF survey

Location: Theater B in the Exhibit Hall

Speaker: – Dartmouth Health Children's

9:00 AM - 9:50 AM PDT

RFPT07.2- Who’s left behind? Understanding gaps in CFTR modulator use among eligible Canadians with CF

Location: Theater B in the Exhibit Hall

Speaker: – Cystic Fibrosis Canada

9:00 AM - 9:50 AM PDT

RFPT07.3- Assessing the effectiveness of the current CFTR modulator donation program for improving global treatment access

Location: Theater B in the Exhibit Hall

Speaker: – Imperial College London

9:00 AM - 9:50 AM PDT

RFPT07.4- Global disparities in time from marketing authorization to reimbursement for elexacaftor/tezacaftor/ivacaftor

Location: Theater B in the Exhibit Hall

Speaker: – Imperial College London

9:00 AM - 9:50 AM PDT

RFPT07.5- Community Voice: Ten years of increasing representation and centering CF community perspectives in CF Foundation programs and research

Location: Theater B in the Exhibit Hall

Speaker: – CF Foundation

9:00 AM - 9:50 AM PDT

RFPT07.6- Supporting the Hispanic CF community through an expansion of CF Peer Connect

Location: Theater B in the Exhibit Hall

Speaker: – Cystic Fibrosis Foundation

9:00 AM - 9:50 AM PDT

RFPT07.7- Uncovering health disparities: CF health outcomes of American Indian/Alaska Native individuals receiving care in Oklahoma

Location: Theater B in the Exhibit Hall

Speaker: – University of Oklahoma- Tulsa School of Community Medicine

9:00 AM - 9:50 AM PDT

RFPT07.8- An assessment of disparities of the Texas Newborn Screen utilizing the Hologic 40+2 Genetic Panel

Location: Theater B in the Exhibit Hall

Speaker: – Pediatric Pulmonary, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, USA

9:00 AM - 11:00 AM PDT

Coffee Break

Location: Exhibit Hall

9:00 AM - 5:00 PM PDT

Exhibit Hall Hours

9:45 AM - 10:30 AM PDT

Registry Classroom- Office Hours (Q/A)

Location: 602-Nooksack (Hyatt Regency)

10:15 AM - 11:45 AM PDT

TPS04--Lungs & Beyond

Location: Theater A Exhibit Hall

Chair: – University of Alabama-Birmingham

Chair: – National Jewish Health

CLIN

10:15 AM - 11:45 AM PDT

TPS04.1- Decreased elexacaftor/tezacaftor/ivacaftor concentrations during pregnancy: the MAYFLOWERS PK Sub-study

Location: Theater A Exhibit Hall

Speaker: – Univ of North Carolina Chapel

10:15 AM - 11:45 AM PDT

TPS04.2- Outcomes in first year of life for infants with exposure to elexacaftor/tezacaftor/ivacaftor (ETI) in utero

Location: Theater A Exhibit Hall

Speaker: – Johns Hopkins All Children's Hospital

10:15 AM - 11:45 AM PDT

TPS04.4- Impact of highly effective modulator therapy on chronic rhinosinusitis and olfactory dysfunction

Location: Theater A Exhibit Hall

Speaker: – University of Michigan Medical School

10:15 AM - 11:45 AM PDT

TPS04.5- CANCELLED: The power of breath: An innovative diagnostic for P. aeruginosa CF lung infections

Location: Theater A Exhibit Hall

Speaker: – Arizona State University

10:15 AM - 11:45 AM PDT

TPS04.6- Proteomic analysis of exhaled breath condensate to identify protein signatures of infection in people with CF

Location: Theater A Exhibit Hall

Speaker: – University of Kansas Medical Center

10:15 AM - 11:45 AM PDT

TPS04.7- The role and impact of antifungals in the treatment of allergic bronchopulmonary aspergillosis in CF

Location: Theater A Exhibit Hall

Speaker: – University of Pennsylvania Perelman School of Medicine

10:15 AM - 11:45 AM PDT

TPS04.8- CForwaRD: Personalized CFRD risk assessment looking ahead 1, 2, and 5 years after the most recent OGTT

Location: Theater A Exhibit Hall

Speaker: – Johns Hopkins University

10:15 AM - 11:45 AM PDT

TPS04.9- Pancreatic cancer risk in adults living longer with CF: Early insights from an MRCP-based screening protocol

Location: Theater A Exhibit Hall

Speaker: – Boston Children's Hospital

10:15 AM - 11:45 AM PDT

TPS04.10- Impact of elexacaftor/tezacaftor/ivacaftor on hepatic status after 4-5 years: Results of the combined PROMISE and RECOVER studies

Location: Theater A Exhibit Hall

Speaker: – University of Colorado SOM and Children's Hospital Colorado

10:15 AM - 12:15 PM PDT

W18--Bringing Health Equity into Care

Location: 435

Chair: – Brigham and Women’s Hospital, Division of Global Health Equity and Medstar Washington Hospital Center

Chair: – University of Pittsburgh

HEACSW/PSYCHCLIN

10:15 AM - 12:15 PM PDT

W18.1- Progression of CF c.are in Egypt

Location: 435

Speaker: – University of Michigan Health

10:15 AM - 12:15 PM PDT

W18.2- Holding complexity: Sustaining equity efforts in CF Care through reflection, accountability, and adaptation

Location: 435

Speaker: – Boston Children's Hospital

10:15 AM - 12:15 PM PDT

W18.3- Equitable care: MyChart Spanish

Location: 435

Speaker: – Children's Healthcare of Atlanta

10:15 AM - 12:15 PM PDT

W18.4- “But you’re Black and not Skinny”: Photovoice insights on racism and structural inequities among BIPOC individuals with CF

Location: 435

Speaker: – UNC

10:15 AM - 12:15 PM PDT

W18.5- Intersectional lived experiences of LGBTQIA+ people with CF: A qualitative interview study

Location: 435

Speaker: – West Virginia University Department of Pediatrics

10:15 AM - 12:15 PM PDT

W19--Epidemiology & Clinical Impact of Infection in CF

Location: Ballroom 3 (Level 5)

Chair: – University of Iowa

Chair: – University of Colorado

IMICLIN

10:15 AM - 12:15 PM PDT

W19.1- Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on healthcare resource utilization (HCRU) over three years in LONGITUDE – a UK CF Registry observational study

Location: Ballroom 3 (Level 5)

Speaker: – Vertex Pharmaceuticals

10:15 AM - 12:15 PM PDT

W19.2- Risk factors for pulmonary exacerbation in people with CF taking elexacaftor/tezacaftor/ivacaftor who stop chronic daily therapies

Location: Ballroom 3 (Level 5)

Speaker: – Children's Hospital of Philadelphia

10:15 AM - 12:15 PM PDT

W19.3- Epidemiology of Pseudomonas aeruginosa infection before and after the 2013 Infection Prevention and Control Guidelines

Location: Ballroom 3 (Level 5)

Speaker: – University of Michigan Medical School

10:15 AM - 12:15 PM PDT

W19.5- Evaluating the clinical utility of oropharyngeal swabs from children with CF on elexacaftor/tezacaftor/ivacaftor using shotgun metagenomics

Location: Ballroom 3 (Level 5)

Speaker: – University of Iowa

10:15 AM - 12:15 PM PDT

W20--Cutting-edge Clinical Trials: Insights & Updates

Location: Flex A (Level 2)

Chair: – University of North Carolina at Chapel Hill

Chair: – Indiana University

CLIN

10:15 AM - 12:15 PM PDT

W20.1- Comparative clinical outcomes of Trikafta® versus bioequivalent ETI formulations in the management of CF in adults: a real world experience

Location: Flex A (Level 2)

Speaker: – HIGA R Rossi

10:15 AM - 12:15 PM PDT

W20.2- A Phase II study (CLAIRAFLY®) evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of the DPP1 (CatC) inhibitor BI 1291583 in cystic fibrosis: Effects of CFTR modulator therapy use

Location: Flex A (Level 2)

Speaker: – Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine

10:15 AM - 12:15 PM PDT

W20.3- Safety, tolerability, and pharmacokinetics of novel NBD1 stabilizers SION-719 and SION-451 from two phase 1 first-in-human studies

Location: Flex A (Level 2)

Speaker: – Sionna Therapeutics

10:15 AM - 12:15 PM PDT

W20.4- Nutritional decline and glycemic variability as early clinical indicators in pediatric CF patients undergoing CGM: a retrospective cohort analysis

Location: Flex A (Level 2)

Speaker: – Stanford Medicine Children's Health

10:15 AM - 12:15 PM PDT

W20.5- Artificial intelligence integrating gut microbiome multi-omics to predict clinical outcomes in children with CF

Location: Flex A (Level 2)

Speaker: – The University of New South Wales

10:15 AM - 12:15 PM PDT

W21--Updates in Care

Location: 431-432

Chair: – Manchester Adult Cystic Fibrosis Centre, UK

Chair: – UCLA

PT&RT

10:15 AM - 12:15 PM PDT

W21.1- Tutorial video improves huff cough quality in patients with CF using a novel measure to objectively assess technique

Location: 431-432

Speaker: – The Children's Hospital of the King's Daughters

10:15 AM - 12:15 PM PDT

W21.2- Oxygen supplementation in pregnancy with CF: A data-driven assessment

Location: 431-432

Speaker: – Nebraska Medicine

10:15 AM - 12:15 PM PDT

W21.3- Optimizing Health: Virtual program to improve health literacy and self-efficacy for children with CF aged 8-12 years. It’s the GOAT!

Location: 431-432

Speaker: – Primary Children's Hospital

10:15 AM - 12:15 PM PDT

W21.4- Balance and mobility deficits in persons with CF: Neural mechanisms and physical manifestations

Location: 431-432

Speaker: – Oregon Health & Science University (OHSU)

10:15 AM - 12:15 PM PDT

W21.5- Exploring the impact of diaphragmatic breathing exercises on lung function in children with CF

Location: 431-432

Speaker: – Sutter Medical Center

10:15 AM - 12:15 PM PDT

W22--Reprogramming Immune Dysfunction in CF

Location: 436

Chair: – University of Alabama at Birmingham

Chair: – Yale University

APPTTIMI

10:15 AM - 12:15 PM PDT

W22.1- Bioenergetic and metabolic derangements in circulating CF neutrophils are further enhanced by transmigration to the CF airway milieu

Location: 436

Speaker: – Emory University

10:15 AM - 12:15 PM PDT

W22.2- Chronic CF airway disease is driven by MALAT1+ extracellular vesicles via an HDAC11-dependent mechanism

Location: 436

Speaker: – Emory University

10:15 AM - 12:15 PM PDT

W22.3- LAP it up: The role of LC3 Associated Phagocytosis (LAP) in CF

Location: 436

Speaker: – Emory University

10:15 AM - 12:15 PM PDT

W22.4- Restoration of ezrin via calpain inhibition reinstates immune function in CF alveolar macrophages

Location: 436

Speaker: – Yale University School of Medicine

10:15 AM - 12:15 PM PDT

W22.5- T cell memory polyamine metabolism and heterogeneity in CF exacerbation outcomes

Location: 436

Speaker: – National Jewish Health

10:15 AM - 12:15 PM PDT

W23--Enhancing Care Improvements for the Changing CF Landscape

Location: 433-434

Chair: – Children's Hospital of Philadelphia

Chair: – University of Virginia

CLIN

10:15 AM - 12:15 PM PDT

W23.1- Implementing a sustainable process to improve short stature identification and endocrine referral in a pediatric CF clinic

Location: 433-434

Speaker: – Johns Hopkins All Children's Hospital

10:15 AM - 12:15 PM PDT

W23.2- Enhancing CF Care Delivery: A Quality Improvement Initiative to Reduce Wait Times and Strengthen Patient Partnership

Location: 433-434

Speaker: – Alfred Health

10:15 AM - 12:15 PM PDT

W23.3- Improving access to audiology diagnostic testing in an adult CF program

Location: 433-434

Speaker: – UC San Diego Health

10:15 AM - 12:15 PM PDT

W23.4- Expanded use of remote objective monitoring during telehealth visits for people with CF experiencing acute symptoms: The EUROPA Project

Location: 433-434

Speaker: – Johns Hopkins University

10:15 AM - 12:15 PM PDT

W23.5- Reaching a new milestone: The need to screen for menopause in women with CF

Location: 433-434

Speaker: – National Jewish Health

10:15 AM - 12:15 PM PDT

W24--New Psychosocial Interventions

Location: 423-425

Chair: – University of Kentucky

Chair: – St. Michael's Hospital, Unity Health Toronto

SW/PSYCH

10:15 AM - 12:15 PM PDT

W24.1- Single-item mental health monitoring: Sensitivity and specificity of the Distress Thermometer in CF

Location: 423-425

Speaker: – Michigan Medicine Department of Pediatrics, CS Mott Children's Hospital

10:15 AM - 12:15 PM PDT

W24.2- Development of a General Mental Health Screener (GEMS-CF) and Modulator Side-Effects (GEMS-Mod-SE) Measure: Preliminary psychometric properties

Location: 423-425

Speaker: – Joe DiMaggio Children’s Hospital

10:15 AM - 12:15 PM PDT

W24.3- Pilot study of the PACE-CF Pain Acknowledgement, Coping, and Empowerment intervention for adults

Location: 423-425

Speaker: – University of Kansas Medical Center

10:15 AM - 12:15 PM PDT

W24.4- Stress less, live more: Coping and Learning to Manage Stress (CALM) telehealth sessions help alleviate severe depression and anxiety symptoms in adults with CF

Location: 423-425

Speaker: – National Jewish Health

10:15 AM - 12:15 PM PDT

W24.5- Creating connection for adults with CF: The impact of CF Circles

Location: 423-425

Speaker: – Cystic Fibrosis Foundation

10:15 AM - 12:15 PM PDT

W25--What Does This Button Do? - Innovations in CF Pharmacotherapy

Location: Signature Room (Level 5)

Chair: – The Hospital for Sick Children

Chair: – Child

PHARM

10:15 AM - 12:15 PM PDT

W25.1- National survey of treatment gaps in type 2 inflammation and CF

Location: Signature Room (Level 5)

Speaker: – Intermountain Medical Center

10:15 AM - 12:15 PM PDT

W25.2- Financial & administrative impacts on people with CF, pharmacists, and pharmacy technicians at CFF-accredited care centers following changes in pharmaceutical limited distribution network

Location: Signature Room (Level 5)

Speaker: – University of Iowa Health Care

10:15 AM - 12:15 PM PDT

W25.3- Impact of pharmacogenomic profiling on medication use in pediatric patients with CF

Location: Signature Room (Level 5)

Speaker: – UNC Children's Hospital

10:15 AM - 12:15 PM PDT

W25.4- Physiologically based pharmacokinetic of elexacaftor/tezacaftor/ivacaftor in children with CF: extrapolation of the dosing regimen in children under 2 years of age

Location: Signature Room (Level 5)

Speaker: – UMR-S 1341, Pharmacologie Et Évaluation Des Thérapeutiques Chez L'enfant Et La Femme Enceinte Université Paris Cité, Paris, France.

10:15 AM - 12:15 PM PDT

W25.5- Modeling a single variable-time measurement of elexacaftor/tezacaftor/ivacaftor in adults

Location: Signature Room (Level 5)

Speaker: – University of North Carolina- Chapel Hill/ National Jewish Health

Speaker:

10:15 AM - 12:15 PM PDT

W26--Best Abstracts in Endocrinology

Location: Ballroom 1 (Level 5)

Chair: – UPMC Children's Hospital of Pittsburgh

Chair: – University of Pennsylvania Perelman School of Medicine

CLIN

10:15 AM - 12:15 PM PDT

W26.1- Bone mineral density in young children with CF pre- and post-elexacaftor/tezacaftor/ivacaftor – The BEGIN Study

Location: Ballroom 1 (Level 5)

Speaker: – Children's Hospital of Philadelphia

10:15 AM - 12:15 PM PDT

W26.2- Baseline lean mass deficits in adolescents and adults with CF persist 24-30m following elexacaftor/tezacaftor/ivacaftor initiation

Location: Ballroom 1 (Level 5)

Speaker: – Children's Hospital of Philadelphia

10:15 AM - 12:15 PM PDT

W26.3- Evaluation of testosterone levels in males with CF before and after initiation of elexacaftor/tezacaftor/ivacaftor: Data from the PROMISE study

Location: Ballroom 1 (Level 5)

Speaker: – UT Southwestern

10:15 AM - 12:15 PM PDT

W26.4- Pregnancy and early parenthood does not have a detrimental impact on CF-health status in women under a dedicated CF Maternal Health Service in the elexacaftor/tezacaftor/ivacaftor era

Location: Ballroom 1 (Level 5)

Speaker: – Royal Brompton Hospital

10:15 AM - 12:15 PM PDT

W26.5- Screening for diabetes and pre-diabetes in CF using a non-fasting 50g 1 hour oral glucose challenge test

Location: Ballroom 1 (Level 5)

Speaker: – University of Colorado, Anschutz Medical Campus

10:15 AM - 12:15 PM PDT

W27--LEAPP in the Best Abstracts in Nursing & Advance Practice Providers

Location: 420-422

Chair: – University of Minnesota

Chair: – Doernbecher Children's Hospital

Chair: – Stanford University

NRS

10:15 AM - 12:15 PM PDT

W27.1- Increasing respiratory syncytial virus (RSV) vaccination rates in adult CF clinic

Location: 420-422

Speaker: – UC San Diego Health

10:15 AM - 12:15 PM PDT

W27.2- Transitioning to adult care: Exploring the experiences and challenges of people with CF in the post-HEMT era

Location: 420-422

Speaker: – University of Cincinnati -

10:15 AM - 12:15 PM PDT

W27.3- Improving the immunization rates in a large paediatric CF clinic

Location: 420-422

Speaker: – QLD HEALTH

10:15 AM - 12:15 PM PDT

W28--Nutritional Breakthroughs: A Workshop on Evidenced-based Nutrition

Location: Ballroom 2 (Level 5)

Chair: – University Health

NTR

10:15 AM - 12:15 PM PDT

W28.1- An evaluation of fecal metabolomics and markers of intestinal integrity in individuals with advanced CF liver disease (aCFLD) and the effect of elexacaftor-tezacaftor-ivacaftor (ETI)

Location: Ballroom 2 (Level 5)

Speaker: – Division of Gastroenterology and Hepatology, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA, USA

10:15 AM - 12:15 PM PDT

W28.2- Multivariate classification of gut symptoms in people with CF identifies four phenotypes

Location: Ballroom 2 (Level 5)

Speaker: – Imperial College

10:15 AM - 12:15 PM PDT

W28.3- Gut research advancing a mechanistic & personalised understanding of symptoms in CF (GRAMPUS-CF): clinical manifestations

Location: Ballroom 2 (Level 5)

Speaker: – Queen's University Belfast

10:15 AM - 12:15 PM PDT

W28.4- Fecal microbiota changes in people with CF after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the PROMISE study

Location: Ballroom 2 (Level 5)

Speaker: – UCSF Benioff Children's Hospital Oakland

10:15 AM - 12:15 PM PDT

W28.5- G542X small intestine exhibit modest inflammation without structural damage

Location: Ballroom 2 (Level 5)

Speaker: – Case Western Reserve University

10:15 AM - 12:15 PM PDT

W29--Don’t STOP Believing: Solutions to Readthrough of PTCs

Location: Terrace Suite (Level 4)

Chair: – FCUL-Faculty of Sciences, University of Lisboa

Chair: – University of Rochester School of Medicine and Dentistry

PTAC/CFTR

10:15 AM - 12:15 PM PDT

W29.1- Genome-Wide KO Screen (GWS) to uncover genes promoting Premature Termination Codon readthrough

Location: Terrace Suite (Level 4)

Speaker: – Cystic Fibrosis Foundation

10:15 AM - 12:15 PM PDT

W29.2- CFTR glutamic acid nonsense mutations are rescued by a newly engineered suppressor transfer RNA in a variant-dependent manner

Location: Terrace Suite (Level 4)

Speaker: – Indiana University

10:15 AM - 12:15 PM PDT

W29.3- Targeted eRF3a degradation amplifies nonsense mutation readthrough in a CF murine model

Location: Terrace Suite (Level 4)

Speaker: – Case Western Reserve University.

10:15 AM - 12:15 PM PDT

W29.4- Small molecules as Aminoglycoside Enhancers to promote readthrough for the treatment of CF

Location: Terrace Suite (Level 4)

Speaker: – Heersink School of Medicine, University of Alabama at Birmingham, Department of Biochemistry and Molecular Genetics

10:15 AM - 12:15 PM PDT

W29.5- Discovery of non-aminoglycoside small molecules that enhance eRF3 degrader-induced translational readthrough of CFTR nonsense mutations

Location: Terrace Suite (Level 4)

Speaker: – Cystic Fibrosis Foundation

10:15 AM - 12:15 PM PDT

TPS04.3- Lung function decline persists among healthy children with CF taking elexacaftor/tezacaftor/ivacaftor

Location: Theater A Exhibit Hall

Speaker: – Cincinnati Children's Hospital Medical Center

10:45 AM - 11:30 AM PDT

Registry Classroom- Office Hours (Q/A)

Location: 602-Nooksack (Hyatt Regency)

12:15 PM - 1:15 PM PDT

Poster Session: All Odd Numbered Posters

12:15 PM - 2:30 PM PDT

Visit Exhibits and Posters (Refreshments Available)

12:30 PM - 1:20 PM PDT

FSC05--A Conversation with Kecia Nelson

Location: Fireside Chat A Exhibit Hall

Speaker: – MU Children's Hospital

Facilitator: – Hartford Healthcare, Hartford, CT, USA

SW/PSYCH

12:30 PM - 1:20 PM PDT

FSC06--A Conversation with Greg Sawicki

Location: Fireside Chat B Exhibit Hall

Speaker: – Boston Children's Hospital

Facilitator: – CF Foundation

HEAC

12:30 PM - 1:30 PM PDT

Navigating the Past, Present, and Future of CFTR Dysfunction Through Sweat Chloride

Location: 343-344

Speaker:

Speaker: – Northwestern University

12:30 PM - 1:30 PM PDT

Junior Investigators Competition: Top 5 Best Abstract in Clinical Research

Location: 323-325

Chair: – Massachusetts General Hospital/Harvard Medical School

Chair: – Riley Hospital for Children at Indiana University Health

Judge: – University of Pennsylvania

Judge: – Joe DiMaggio Children’s Hospital

Judge: – Medical College of Wisconsin / Children's Wisconsin

Judge:

Judge: – Cystic Fibrosis Foundation

12:30 PM - 1:30 PM PDT

Junior Investigators Competition: Top 5 Best Abstract in Basic Science

Location: 347-348

Chair: – Emory University School of Medicine

Chair: – Columbia University Irving Medical Centre

Judge:

Judge: – University of Washington and VA Puget Sound Health Care System

Judge: – University of Michigan

Judge: – University of Washington

Judge: – Yale University

Judge: – University of North Carolina

12:30 PM - 2:00 PM PDT

Adult Program Directors' Meeting

Location: Columbia Ballroom C (Hyatt Regency)

12:30 PM - 2:00 PM PDT

Pediatric Program Directors' Meeting

Location: Columbia Ballroom D (Hyatt Regency)

12:30 PM - 2:00 PM PDT

Program Coordinators' Meeting

Location: Columbia Ballroom A (Hyatt Regency)

1:15 PM - 2:15 PM PDT

Poster Session: All Even Numbered Posters

1:30 PM - 2:20 PM PDT

FSC07--A Conversation with Katie McDonald

Location: Fireside Chat A Exhibit Hall

Speaker: – Primary Children's Hospital

Facilitator: – Primary Children's Cystic Fibrosis Center

NTR

1:30 PM - 2:20 PM PDT

FSC08--A Conversation with Janet Garbarz

Location: Fireside Chat B Exhibit Hall

Speaker: – Cook Children's

Facilitator: – Rush University Medical Center

NRS

2:00 PM - 2:15 PM PDT

Wellness Break- Lower Body Relaxation

Location: Exhibit Hall Foyer

2:30 PM - 3:15 PM PDT

Registry Classroom- PortCF (Introduction and Tools)

Location: 602-Nooksack (Hyatt Regency)

2:30 PM - 4:00 PM PDT

TPS05--Biomarkers of Disease Severity & Outcome Measures of Therapeutic Efficacy

Location: Theater A Exhibit Hall

Chair: – Riley Hospital for Children at Indiana University Health

Chair: – Arkansas Children's Hospital/Arkansas Children's Research Institute

APPTTCLIN

2:30 PM - 4:00 PM PDT

TPS05.1- Parameter D: A novel biomarker to detect small airway disease through spirometry in CF

Location: Theater A Exhibit Hall

Speaker: – UAB

2:30 PM - 4:00 PM PDT

TPS05.3- Continuous glucose monitoring in young children with cystic fibrosis: a BEGIN sub-study

Location: Theater A Exhibit Hall

Speaker: – University of Iowa

2:30 PM - 4:00 PM PDT

TPS05.4- Changes in sweat chloride concentrations following CFTR modulator treatment and association with antibiotic usage in adolescents and adults with CF

Location: Theater A Exhibit Hall

Speaker: – Department of Pulmonary Medicine, Division of Cystic Fibrosis, University Medicine Essen -Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.

2:30 PM - 4:00 PM PDT

TPS05.5- Maximizing benefits with early CFTR modulator treatment: Lower sweat chloride is associated with improved clinical outcomes in children aged 6 to 11 years

Location: Theater A Exhibit Hall

Speaker: – Vertex Pharmaceutical

2:30 PM - 4:00 PM PDT

TPS05.6- Sweat sodium: chloride ratio differs in people with CF by CFTR modulator treatment status

Location: Theater A Exhibit Hall

Speaker: – University of Colorado School of Medicine

2:30 PM - 4:00 PM PDT

TPS05.7- Evaluation of the variability of exhaled breath profiles for the detection of Pseudomonas aeruginosa infections in CF: A longitudinal study

Location: Theater A Exhibit Hall

Speaker: – University of British Columbia

2:30 PM - 4:00 PM PDT

TPS05.8- Volatile biomarkers can differentiate methicillin-resistant and small-colony variant S. aureus subtypes

Location: Theater A Exhibit Hall

Speaker: – Arizona State University

2:30 PM - 4:00 PM PDT

TPS05.9- Is epigenetic age a marker of CF severity and drug response?

Location: Theater A Exhibit Hall

Speaker: – The Hospital for Sick Children

2:30 PM - 4:30 PM PDT

S13--CF Endocrinology Across the Lifespan

Location: 431-432

Chair: – University of Texas Health San Antonio

Chair: – University of Florida - Gainesville

CLIN

2:30 PM - 4:30 PM PDT

S13.1- Updates on Growth and Puberty

Location: 431-432

Speaker: – Yale Medical Center

2:30 PM - 4:30 PM PDT

S13.2- CF-Bone Disease: From Childhood to Adulthood

Location: 431-432

Speaker: – Johns Hopkins University

2:30 PM - 4:30 PM PDT

S13.3- Male Endocrine and Reproductive Health

Location: 431-432

Speaker: – Rutgers Urology

2:30 PM - 4:30 PM PDT

S13.4- Modern CFRD: Devices, Expanding Therapies, and Addressing Obesity

Location: 431-432

Speaker: – University of Florida - Gainesville

2:30 PM - 4:30 PM PDT

S14--Molecular Basis of Persistent Infection

Location: Ballroom 1 (Level 5)

Chair: – University of Alabama at Birmingham

Chair: – University of Maryland - Baltimore

IMI

2:30 PM - 4:30 PM PDT

S14.1- Mechanisms of Staphylococcus Aureus Pathoadaptation in CF

Location: Ballroom 1 (Level 5)

Speaker: – University of Münster

2:30 PM - 4:30 PM PDT

S14.2- Pseudomonas Aeruginosa Persistence in the CF Airways

Location: Ballroom 1 (Level 5)

Speaker: – University of Washington

2:30 PM - 4:30 PM PDT

S14.3- Polymicrobial Mechanisms of Bacterial Persistence in CF

Location: Ballroom 1 (Level 5)

Speaker: – Indiana University Bloomington

2:30 PM - 4:30 PM PDT

S14.4- Anaerobes and Emerging CF Pathogens

Location: Ballroom 1 (Level 5)

Speaker: – Children's Hospital of Philadelphia/UPenn

2:30 PM - 4:30 PM PDT

S15--From Crisis to Care: Tackling the Lung Transplant Journey

Location: 423-425

Chair: – Northwell Health

Chair: – University of California, Los Angeles (UCLA)

SW/PSYCH

2:30 PM - 4:30 PM PDT

S15.1- Patient / Caregiver VIDEO

Location: 423-425

Community Speaker: – Private

Community Speaker: – Queens University of Charlotte

2:30 PM - 4:30 PM PDT

S15.2- Psychotherapy and BOLT: Insights from a Therapist and CF Family Member

Location: 423-425

Speaker: – Inova Fairfax

2:30 PM - 4:30 PM PDT

S15.3- Improved Alcohol Use Screening & Other Pearls of Wisdom from a CF and LT MD

Location: 423-425

Speaker: – UCLA

2:30 PM - 4:30 PM PDT

S15.4- One Pediatric Patient Perspective: A CF MD Perspective of the challenges of Pre/Post Transplant Care

Location: 423-425

Speaker: – West Virginia University

2:30 PM - 4:30 PM PDT

S16--The Promise of Nucleic Acid-Based Therapies in CF: Progress & Prospects

Location: 420-422

Chair: – Washington University in St. Louis

Chair: – Division of Pulmonary Medicine, Cincinnati Children’s Hospital, Cincinnati, Ohio, USA

PTAC/CFTR

2:30 PM - 4:30 PM PDT

S16.1- Progress on Antisense Oligonucleotide Therapies in CF

Location: 420-422

Speaker: – Hebrew University

2:30 PM - 4:30 PM PDT

S16.2- Lentiviral Gene Therapy – The Journey Into the Clinic

Location: 420-422

Speaker: – National Heart and Lung Institute, Imperial College London

2:30 PM - 4:30 PM PDT

S16.3- Editing the CFTR Gene

Location: 420-422

Speaker: – Division of Pulmonary Medicine, Cincinnati Children’s Hospital, Cincinnati, Ohio, USA

2:30 PM - 4:30 PM PDT

S16.4- Real-world Challenges & Perspectives

Location: 420-422

Speaker: – Washington University in St. Louis

2:30 PM - 4:30 PM PDT

S17--Early Diagnosis vs. Late Diagnosis: Compare & Contrast

Location: Signature Room (Level 5)

Chair: – NYU

Chair: – UW Health

NRS

2:30 PM - 4:30 PM PDT

S17.1- Diagnosis Mixed Bag: Newborn to Adult and Everything in Between

Location: Signature Room (Level 5)

Speaker: – Dartmouth Hitchcock

2:30 PM - 4:30 PM PDT

S17.2- Teenage CF Diagnosis: Challenges and Successes

Location: Signature Room (Level 5)

Speaker: – University of Utah

2:30 PM - 4:30 PM PDT

S17.3- Navigating a New Diagnosis- The First Year of Life

Location: Signature Room (Level 5)

Speaker: – University of Utah

2:30 PM - 4:30 PM PDT

S17.4- A Little Late, but Look at Me Now

Location: Signature Room (Level 5)

Speaker: – Indiana University Adult CF Center

2:30 PM - 4:30 PM PDT

S18--Individualizing Nutrition Care: A Health Behavior Perspective

Location: Flex A (Level 2)

Chair: – UT Health San Antonio

Chair: – Baylor Scott and white

NTR

2:30 PM - 4:30 PM PDT

S18.1- Pros and Cons of GLP-1 agonists

Location: Flex A (Level 2)

Speaker:

2:30 PM - 4:30 PM PDT

S18.2- Individual Experience of Body Image Changes with Modulators

Location: Flex A (Level 2)

Speaker: – Patient with CF

2:30 PM - 4:30 PM PDT

S18.3- Individual Experience of Body Image Changes with Modulators

Location: Flex A (Level 2)

Speaker: – Patient with Cystic Fibrosis

2:30 PM - 4:30 PM PDT

S18.4- Weight Inclusive Approach to Counseling Patients and Caregivers

Location: Flex A (Level 2)

Speaker: – Cincinnati Children's Hospital Medical Center, Divisions of Behavioral Medicine and Clinical Psychology & Pulmonary Medicine

2:30 PM - 4:30 PM PDT

S19--Don’t Sweat It: Navigating the Relationship Between Sweat Chloride & Clinical Outcomes in CF

Location: 435

Chair: – University of Washington

Chair: – Children's Hospital Colorado, Univ. of Colorado Anschutz Med. Campus

CLIN

2:30 PM - 4:30 PM PDT

S19.1- Is Sweating Enough? Biomarkers of CFTR Function

Location: 435

Speaker: – Charité - Universitätsmedizin Berlin

2:30 PM - 4:30 PM PDT

S19.2- Relationship Between Genotype, CFTR Activity, and Clinical Phenotype

Location: 435

Speaker: – Johns Hopkins University

2:30 PM - 4:30 PM PDT

S19.3- Sweat Signals: Use of Sweat Chloride in Clinical Trials of CFTR Modulators

Location: 435

Speaker: – Department of Pediatrics, Division of Pulmonology, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine

2:30 PM - 4:30 PM PDT

S19.4- Promise and Pitfalls in Sweat Chloride Use for Clinical Monitoring and Therapeutics Development

Location: 435

Speaker: – Children's Hospital Colorado, Univ. of Colorado Anschutz Med. Campus

2:30 PM - 4:30 PM PDT

S20--Modulator Effects on Different Organ Systems

Location: Terrace Suite (Level 4)

Chair: – Boston Children's Hospital

Chair: – Advocate Children's Hospital

EPPPTAC/CFTR

2:30 PM - 4:30 PM PDT

S20.1- To β or not to β: The Effects CFTR Modulator Therapy on Insulin Secretion and Glucose Homeostasis

Location: Terrace Suite (Level 4)

Speaker: – Hasbro Children's Hospital

2:30 PM - 4:30 PM PDT

S20.2- Gastrointestinal Impact of CFTR Modulators

Location: Terrace Suite (Level 4)

Speaker: – Division of Gastroenterology and Hepatology, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA, USA

2:30 PM - 4:30 PM PDT

S20.3- Beyond the Channel: Immune Implications of CFTR Modulation

Location: Terrace Suite (Level 4)

Speaker: – Emory University/Childrens Atlanta

2:30 PM - 4:30 PM PDT

S20.4- CFTR Modulators and the Central Nervous System

Location: Terrace Suite (Level 4)

Speaker: – Massachusetts General Hospital/Harvard Medical School

2:30 PM - 4:30 PM PDT

S21--For Your Consideration: A Debate on De-escalating Therapies?

Location: 427-429

Chair: – Vancouver, Canada

Chair: – Wellstar MCG Health Children's Hospital of Georgia

PT&RT

2:30 PM - 4:30 PM PDT

Pro Argument: De-Escalation of Airway Clearance

Location: 427-429

Speaker: – BC Childrens Hospital

2:30 PM - 4:30 PM PDT

S21.2- Con Argument: De-Escalation of Airway Clearance

Location: 427-429

Speaker: – Royal Brompton Hospital, Guys and St Thomas's NHS Foundation Trust and NHLI, Imperial College, London

2:30 PM - 4:30 PM PDT

S21.3- Pro Argument: De-Escalation of Mucolytics

Location: 427-429

Speaker: – UH Cleveland Medical Center

2:30 PM - 4:30 PM PDT

S21.4- Con Argument: De-Escalation of Mucolytics

Location: 427-429

Speaker: – University of North Carolina at Chapel Hill

2:30 PM - 4:30 PM PDT

S21.5- Pro Argument: De-Escalation of Anti-Pseudomonals

Location: 427-429

Speaker: – Wellstar MCG- Children's Hospital of Georgia

2:30 PM - 4:30 PM PDT

S21.6- Con Argument: De-Escalation of Anti-Pseudomonals

Location: 427-429

Speaker: – Riley Hospital for Children at Indiana University Health

2:30 PM - 4:30 PM PDT

S22--Cell Biology Meets Gene Therapy: Challenges of Restoring CFTR Expression in the Lung

Location: Ballroom 2 (Level 5)

Chair: – University of Toronto & The Hospital for Sick Children

Chair: – University of Saskatchewan

APPTTPTAC/CFTR

2:30 PM - 4:30 PM PDT

S22.1- Healing the Airway: Human Pluripotent Stem Cell-based Airway Regeneration

Location: Ballroom 2 (Level 5)

Speaker: – Icahn School of Medicine at Mount Sinai

2:30 PM - 4:30 PM PDT

S22.2- iPSC-Based Approaches to Uncover Ionocyte Function and Therapeutic Potential in CF

Location: Ballroom 2 (Level 5)

Speaker: – Boston Children's Hospital

2:30 PM - 4:30 PM PDT

S22.3- Hitting the Target: Challenges and Progress in Delivery to Airway Epithelial Cells

Location: Ballroom 2 (Level 5)

Speaker: – University of Iowa

2:30 PM - 4:30 PM PDT

S22.4- Design and Development of Lipid Nanoparticles for Durable CFTR Gene Correction in Lung Stem Cells

Location: Ballroom 2 (Level 5)

Speaker: – University of Texas Southwestern Medical Center

2:30 PM - 4:30 PM PDT

S23--Year(s) in Review

Location: 433-434

Chair: – Rainbow Babies and Children's Hospital

Chair: – University of Washington

CLIN

2:30 PM - 4:30 PM PDT

S23.1- Quality Improvement and the CF Learning Network (CFLN)

Location: 433-434

Speaker: – Seattle Children's Hospital/UW

2:30 PM - 4:30 PM PDT

S23.2- Lung Transplant and the CF Lung Transplant Consortium (CFLTC)

Location: 433-434

Speaker: – University of Pittsburgh

2:30 PM - 4:30 PM PDT

S23.3- Adherence and the Success with Therapies Research Consortium (STRC)

Location: 433-434

Speaker: – Johns Hopkins University School of Medicine

2:30 PM - 4:30 PM PDT

S23.4- Updates in Pain and Review of Recent Guidelines

Location: 433-434

Speaker: – Emory University

Speaker: – UNC Chapel Hill

Community Speaker: – Cystic Fibrosis Foundation

2:30 PM - 4:30 PM PDT

S24--Beyond Boundaries: Protecting & Supporting Optimal Care for All People with CF

Location: Ballroom 3 (Level 5)

Chair: – University of Virginia

Chair: – Boston Children's Hospital

Chair: – University of Alabama at Birmingham

HEACSW/PSYCHNRS

2:30 PM - 4:30 PM PDT

S24.1- Health Needs and Perspectives of LGBTQIA+ People with CF

Location: Ballroom 3 (Level 5)

Speaker: – West Virginia University School of Medicine

2:30 PM - 4:30 PM PDT

S24.2- Immigrant health "Know Your Rights"

Location: Ballroom 3 (Level 5)

Speaker: – Seattle Children's Hospital

Speaker:

2:30 PM - 4:30 PM PDT

S24.3- Health Care Cost and Access in the Current Era

Location: Ballroom 3 (Level 5)

Speaker: – Cystic Fibrosis Foundation

2:30 PM - 4:30 PM PDT

S24.4- Men's Reproductive Health

Location: Ballroom 3 (Level 5)

Speaker: – University of Texas at Austin Dell Medical School

2:30 PM - 4:30 PM PDT

S24.5- Panel Discussion

Location: Ballroom 3 (Level 5)

Speaker: – University of Nevada, Las Vegas - School of Nursing

2:30 PM - 4:30 PM PDT

S25--The New L is Liver

Location: 436

Chair: – Boston Children's Health Physicians

Chair: – Yale University

CLIN

2:30 PM - 4:30 PM PDT

S25.1- Liver Injury in CF Patients

Location: 436

Speaker: – University of Colorado SOM and Children's Hospital Colorado

2:30 PM - 4:30 PM PDT

S25.2- Liver Nutrition in CF Patients

Location: 436

Speaker: – University of Miami

2:30 PM - 4:30 PM PDT

S25.3- Liver Imaging in pwCF

Location: 436

Speaker: – Nationwide Children's Hospital/The Ohio State University

2:30 PM - 4:30 PM PDT

S25.4- Liver Fibrosis Markers in CF

Location: 436

Speaker: – Baylor College of Medicine

3:00 PM - 4:30 PM PDT

CF Global Data and Research Collaboration

Location: 502-Cowlitz (Hyatt Regency)

3:15 PM - 4:00 PM PDT

Registry Classroom- CFSmart Reports (Introduction & Tools)

Location: 602-Nooksack (Hyatt Regency)

5:00 PM - 6:15 PM PDT

PL2--A Breath of Fresh Age: Redefining Growing Older with CF

Location: Flex C (Level 2)

Speaker: – Boston Children's Hospital

Speaker: – Johns Hopkins Hospital

6:30 PM - 7:30 PM PDT

Black Professional in CF Affinity Group

Location: 439

6:30 PM - 7:30 PM PDT

LGBTQIA+ Professionals in CF Affinity Group

Location: 436

6:30 PM - 7:30 PM PDT

Hispanic Professionals in CF Affinity Group

Location: Paramount Lounge, Level 4

6:30 PM - 8:30 PM PDT

RC Reception

Location: Quinault Ballroom (Hyatt Regency)

7:30 PM - 10:30 PM PDT

Emily's Entourage Reception

Location: 302-Beckler (Hyatt Regency)